CAR-T CELL IN DIFFUSE LARGE B-CELL AND PRIMARY MEDIASTINAL LYMPHOMAS IN REAL LIFE SETTING: A REPORT FROM THE PROSPECTIVE OBSERVATIONAL STUDY OF THE ITALIAN SOCIETY OF HEMATOLOGY.
Author(s): ,
Annalisa Chiappella
Affiliations:
Division of Hematology and Stem Cell Transplantation,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Milano,Italy
,
Anna Guidetti
Affiliations:
Division of Hematology and Stem Cell Transplantation,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Milano,Italy;Chair of Hematology,University of Milano,Milano,Italy
,
Anna Dodero
Affiliations:
Division of Hematology and Stem Cell Transplantation,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Milano,Italy
,
Stefania Bramanti
Affiliations:
Humanitas Clinical and Research Center,IRCCS Rozzano,Rozzano,Italy
,
Pierluigi Zinzani
Affiliations:
Institute of Hematology 'Seràgnoli',University of Bologna,Bologna,Italy
,
Armando Santoro
Affiliations:
Humanitas Clinical and Research Center,IRCCS Rozzano,Rozzano,Italy
,
Beatrice Casadei
Affiliations:
Institute of Hematology 'Seràgnoli',University of Bologna,Bologna,Italy
,
Alice Di Rocco
Affiliations:
Department of Translational and Precision Medicine,Sapienza University of Rome,Roma,Italy
,
Matteo Carrabba
Affiliations:
Hematology and Bone Marrow Transplantation Unit,San Raffaele Hospital, IRCCS Milano,Milano,Italy
,
Patrizia Chiusolo
Affiliations:
Department of Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia,Fondazione Policlinico Universitario A. Gemelli IRCCS,Roma,Italy;Hematology Section, Department of Scienze Radiologiche ed Ematologiche,Università Cattolica del Sacro Cuore di Roma,Roma,Italy
,
Massimo Martino
Affiliations:
Stem Cell Transplant and Cellular Therapies Unit,Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' di Reggio Calabria,Reggio Calabria,Italy
,
Anna Maria Barbui
Affiliations:
Hematology Unit,Azienda Socio Sanitaria Territoriale (ASST), Ospedale Papa Giovanni XXIII di Bergamo,Bergamo,Italy
,
Maria Chiara Tisi
Affiliations:
Cell Therapy and Hematology,San Bortolo Hospital of Vicenza,Vicenza,Italy
,
Rosalba Miceli
Affiliations:
Unit of Clinical Epidemiology and Trial Organization; Department of Applied Research and Technological Development,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Milano,Italy
,
Cristiana Carniti
Affiliations:
Laboratory of Hematology, Division of Hematology and Stem Cell Transplantation,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Milano,Italy
Paolo Corradini
Affiliations:
Division of Hematology and Stem Cell Transplantation,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Milano,Italy;Chair of Hematology,University of Milano,Milano,Italy
EHA Library. Chiappella A. 06/09/21; 325489; EP729
Annalisa Chiappella
Annalisa Chiappella
Contributions
Abstract
Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP729

Type: E-Poster Presentation

Session title: Gene therapy, cellular immunotherapy and vaccination - Clinical

Background
Relapsed/refractory (R/R) diffuse large B-cell (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) have a very poor prognosis with standard chemotherapy. The recently approved axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are anti-CD19 chimeric antigen receptor T cells (CAR-T) that proved very effective in clinical trials and real-life setting. The Italian Society of Hematology (SIE) is conducting a prospective observational trial to evaluate safety and efficacy in patients (pts) treated with axi-cel and tisa-cel.

Aims
of the study are: 1. to register all DLBCL and PMBCL pts candidate to CAR-T in the Italian authorized centers; 2. to evaluate the intention to treat overall response rate (ORR, complete [CR] and partial response [PR]); 3. to evaluate duration of response (DOR), progression free survival (PFS) and overall survival (OS); 4. to evaluate safety in terms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and long-term cytopenia; 5. to evaluate different CAR-T products.

Methods
SIE designed a multicenter prospective observational study, approved by ethics committee of all centersAll pts treated since March 2019 to January 2021, were included into this national study.

Results
126 pts were leukapheresed. Thirteen pts showed a rapid progression (10) or fatal infection (3) during the manufacturing and were not infused. The clinical characteristics of the 113 infused pts were: median age 53 years (19-70), male 64 (57%), stage III/IV 77 (68%), bulky disease 51 (45%); median number of prior lines was 3 (2-7); 33 patients (29%) failed a previous autologous stem cell transplantation and 81 (72%) were primary refractory. For histologies, 59 (52%) were DLBCL, 18 (16%) high-grade B-cell (HGBCL), 23 (20%) PMBCL, 13 (12%) transformed Follicular (tFL). Median lymphocyte count at the apheresis was 810/mm3 (250-8900). Bridging therapy was delivered to 97 pts (86%). All pts received Flu-Cy lymphodepletion. Fifty-nine (52%) received axi-cel and 54 (48%) tisa-cel. Median follow-up time for infused pts was 6.9 months (IQR: 3.13-11.78). At 30-days after the infusion, all the 113 infused pts were evaluable for response: 45 (40%) CR, 35 (31%) PR, with and encouraging ORR of 71%. For the evaluable pts, DOR was 73% (95%CI:62-85) at 6-months and 58% (95%CI:44-77) at 12-months. In the whole series, 6 and 12-months PFS were 54% (95% CI:45-65) and 46% (95%CI:35-59); 6 and 12-months OS were 80% (95%CI:71-88) and 75% (95%CI:65-86), respectively. With the limitation of small number, 6-months PFS were 48% for DLBCL, 62% for HGBCL, 66% for PMBCL and 59% for tFL; 6-months OS by histotype were 78% for DLBCL, 80% for HGBCL, 80% for PMBCL and 92% for tFL. No differences between axi-cel and tisa-cel were reported in terms of OS and PFS. All grade CRS was observed in 87 (77%) of 113 pts, but only 6 (5%) were grade 3 or 4; ICANS was recorded in 31 (27%) patients, but only 11 (10%) were grade 3 or 4. Sixty-one (54%) pts received tocilizumab and 38 (34%) steroids. Cytopenia beyond 30 days was reported in 30 (27%) pts and 27 of them (24%) experienced viral or bacterial infections. No toxic deaths were recorded.

Conclusion
In the real-life, axi-cel and tisa-cel showed an ORR similar to those of the registrative trials, even if almost all pts underwent bridging therapy. The response rate is similar across histotypes and between products. CAR-T toxicity is manageable, relapse beyond 6 months is a rare event. Cytopenias as well as infections are an emerging problem in real-life setting.

Keyword(s): B cell lymphoma, CAR-T, Diffuse large B cell lymphoma, Relapsed lymphoma

Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP729

Type: E-Poster Presentation

Session title: Gene therapy, cellular immunotherapy and vaccination - Clinical

Background
Relapsed/refractory (R/R) diffuse large B-cell (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) have a very poor prognosis with standard chemotherapy. The recently approved axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are anti-CD19 chimeric antigen receptor T cells (CAR-T) that proved very effective in clinical trials and real-life setting. The Italian Society of Hematology (SIE) is conducting a prospective observational trial to evaluate safety and efficacy in patients (pts) treated with axi-cel and tisa-cel.

Aims
of the study are: 1. to register all DLBCL and PMBCL pts candidate to CAR-T in the Italian authorized centers; 2. to evaluate the intention to treat overall response rate (ORR, complete [CR] and partial response [PR]); 3. to evaluate duration of response (DOR), progression free survival (PFS) and overall survival (OS); 4. to evaluate safety in terms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and long-term cytopenia; 5. to evaluate different CAR-T products.

Methods
SIE designed a multicenter prospective observational study, approved by ethics committee of all centersAll pts treated since March 2019 to January 2021, were included into this national study.

Results
126 pts were leukapheresed. Thirteen pts showed a rapid progression (10) or fatal infection (3) during the manufacturing and were not infused. The clinical characteristics of the 113 infused pts were: median age 53 years (19-70), male 64 (57%), stage III/IV 77 (68%), bulky disease 51 (45%); median number of prior lines was 3 (2-7); 33 patients (29%) failed a previous autologous stem cell transplantation and 81 (72%) were primary refractory. For histologies, 59 (52%) were DLBCL, 18 (16%) high-grade B-cell (HGBCL), 23 (20%) PMBCL, 13 (12%) transformed Follicular (tFL). Median lymphocyte count at the apheresis was 810/mm3 (250-8900). Bridging therapy was delivered to 97 pts (86%). All pts received Flu-Cy lymphodepletion. Fifty-nine (52%) received axi-cel and 54 (48%) tisa-cel. Median follow-up time for infused pts was 6.9 months (IQR: 3.13-11.78). At 30-days after the infusion, all the 113 infused pts were evaluable for response: 45 (40%) CR, 35 (31%) PR, with and encouraging ORR of 71%. For the evaluable pts, DOR was 73% (95%CI:62-85) at 6-months and 58% (95%CI:44-77) at 12-months. In the whole series, 6 and 12-months PFS were 54% (95% CI:45-65) and 46% (95%CI:35-59); 6 and 12-months OS were 80% (95%CI:71-88) and 75% (95%CI:65-86), respectively. With the limitation of small number, 6-months PFS were 48% for DLBCL, 62% for HGBCL, 66% for PMBCL and 59% for tFL; 6-months OS by histotype were 78% for DLBCL, 80% for HGBCL, 80% for PMBCL and 92% for tFL. No differences between axi-cel and tisa-cel were reported in terms of OS and PFS. All grade CRS was observed in 87 (77%) of 113 pts, but only 6 (5%) were grade 3 or 4; ICANS was recorded in 31 (27%) patients, but only 11 (10%) were grade 3 or 4. Sixty-one (54%) pts received tocilizumab and 38 (34%) steroids. Cytopenia beyond 30 days was reported in 30 (27%) pts and 27 of them (24%) experienced viral or bacterial infections. No toxic deaths were recorded.

Conclusion
In the real-life, axi-cel and tisa-cel showed an ORR similar to those of the registrative trials, even if almost all pts underwent bridging therapy. The response rate is similar across histotypes and between products. CAR-T toxicity is manageable, relapse beyond 6 months is a rare event. Cytopenias as well as infections are an emerging problem in real-life setting.

Keyword(s): B cell lymphoma, CAR-T, Diffuse large B cell lymphoma, Relapsed lymphoma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies